Home / Blog
Global Plasma Fractionation Revenue Is Nearly 22.9 Billion USD In 2018
Friday, 14 Aug, 2020
Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Plasma Fractionation.

In the last several years, global market of Plasma Fractionation developed rapidly, with an average growth rate of 6.8%. In 2018, global revenue of Plasma Fractionation is nearly 22.9 billion USD.

The classification of Plasma Fractionation includes Coagulation Factor, Immune Globulin, Albumin and Other, in 2018, the revenue of Coagulation Factor is 4460 million USD, with its market share 19.46%. And the revenue market share of Immune Globulin is 51.6% in 2018.

The following manufacturers are covered:
Shire (Baxalta)
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio

Plasma Fractionation is widely used for Immunology, Hematology and Other. The most proportion of Plasma Fractionation is for Immunology, and the proportion is about 28% in 2018.

North America is the largest sales place, with a consumption value market share nearly 39.54% in 2018. Following North America, Europe is the second largest sales place with the revenue market share of 25.36% in 2018. China is an important market of Blood Product in Asia, accounting for 14.71% revenue market share of global market.

Baxter, CSL, Grifols are the leaders of the industry, with 71.85% market share in 2018, and hold key technologies and patents. Other manufactures’ products are used to meet local demand. With further expanding market, there will be more players in the future.